Abstract
Intestinal dysbiosis is implicated in the origins of necrotising enterocolitis and late-onset sepsis in preterm babies. However, the effect of modulators of bacterial growth (e.g. antibiotics) upon the developing microbiome is not well-characterised.
Using high-throughput 16S rRNA gene sequencing combined with contemporaneous clinical data collection, the within-subject relationship between antibiotic administration and microbiome development was assessed, in comparison to preterm infants with minimal antibiotic exposure.
During courses of antibiotics, diversity progression fell in comparison to that seen outside periods of antibiotic use (−0.71units/week vs. +0.63units/week, p<0.01); Enterobacteriaceae relative abundance progression conversely rose (+10.6%/week vs. -8.9%/week, p<0.01). After antibiotic cessation, diversity progression remained suppressed (+0.2units/week, p=0.02).
Antibiotic use has an acute and longer-lasting impact on the developing preterm intestinal microbiome. This has clinical implications with regard to the contribution of antibiotic use to evolving dysbiosis, and affects the interpretation of existing microbiome studies where this effect modulator is rarely accounted for.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work leading to this publication would not have been possible without the generous support of Barts Charity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the London (Chelsea) Research Ethics Committee (Ref: 15/LO/1924).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. The raw sequencing data and metadata were uploaded to a publicly accessible database (The NCBI Sequence Read Archive) under the BioProject accession code PRJNA605031.
